Mylan (MYL) Misses Q4 EPS by 5c

Mylan (MYL) Miss Overshadowed by Mediocre Deal - Guggenheim

After the 4Q15 miss and announcement of the deal to acquire Meda Guggenheim analyst, Louise Chen, remains on the sidelines and kept her Neutral rating on Mylan (NASDAQ: MYL) shares. This acquisition makes strategic sense, but Meda (3% topline, 5% EBITDA growth) does not enhance MYL's sales and earnings profile. This is important ahead of potential generic competition for Epipen in 2H16. No change to... More

RBC Capital Views Mylan's (MYL) Meda Purchase as Desperate - PT to $58

RBC Capital reiterated a Sector Perform rating on Mylan (NASDAQ: MYL), and cut the price target to $58.00 (from $60.00), following the company's announcement that they will acquire Meda for $9.9 billion. Separately, MYL missed 4Q. Neither will help the stock and this deal feels desperate in RBC's... More

Mylan (MYL) Enters Agreement to Acquire Meda in ~$9.9B Deal

Price of SEK 165 per Meda Share at Announcement Represents a Multiple of Approximately 12.9x 2015 Adjusted EBITDA and 8.9x 2015 Adjusted EBITDA with Synergies

Strengthens Mylan's Position as a Diversified Global Pharmaceutical Leader with an Expansive and Growing Portfolio of Specialty, Generic and OTC Products and a Strong, Complementary Therapeutic Presence

Combined Business Will Have Critical Mass across Commercial Channels in Europe, a Leading U.S. Specialty Business, and an Exciting Platform for Growth in Emerging Markets

Expected to Be Immediately Accretive to Mylan Earnings, with Accretion Increasing Significantly after First Full Year (2017) as Synergies Are Realized; Creates... More

Mylan (MYL) to Announce Takeover of Meda - FT

Mylan (NASDAQ: MYL) is set to announce a takeover of Meda, according to the Financial Times. An announcement could come later today.